Afleveringen

  • 121 - Breaking Biotech Week End Wrap Up - Nov 7 , 2026
    9 Nov 2026

    $RYTM

    $RVMD

    $MRNA

    This podcast is powered by Pinecast.

    Toon meer Toon minder
    29 min.
  • 122 - Breaking Biotech Week End Wrap Up - Nov 14, 2026
    15 Nov 2026
    $BEAM $MRK $RVMD
    Toon meer Toon minder
    31 min.
  • 120 - Breaking Biotech Week End Wrap Up - Oct 25th, 2026
    26 Oct 2026
    $MRNA $QGEN $NAUT $IAM
    Toon meer Toon minder
    27 min.
  • 119 - $IVA: Can Lanifibranor Deliver in Phase 3 MASH?
    23 Oct 2026
    Episode Notes

    Inventiva is approaching one of the most important MASH readouts of the year with NATiV3, its pivotal Phase 3 trial of Lanifibranor in F2/F3 MASH.

    In this episode, I break down:

    • The different stages of MASH • The current market opportunity and competitors • Lanifibranor's Phase 2 data • Trial design for NATiV3 • Lanifibranor’s weight-gain and safety profile • Inventiva’s financing, dilution and unusual post-readout capital structure

    NATiV3 could establish lanifibranor as another major MASH therapy — or expose the weaknesses hidden by a small Phase 2 study.

    $IVA #biotech #MASH #NASH #lanifibranor #Inventiva

    Disclaimer: All opinions expressed by Matt (or his guests) in this podcast are solely his (their) opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt (nor his guests) cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt (nor his guests) is/are not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt (nor his guests) does/do not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech

    This podcast is powered by Pinecast.

    Toon meer Toon minder
    35 min.
  • 118 - End of Week Wrap up - Oct 9, 2026
    10 Oct 2026

    End of week wrap up stream.

    Covered $CRBU, $LLY, $MRNA

    This podcast is powered by Pinecast.

    Toon meer Toon minder
    25 min.
  • 117 - End of Week Wrap Up - Oct 2, 2026
    2 Oct 2026

    End of week biotech stream Oct 2, 2026.

    Touched on $KOD, $BEAM, $NKTR.

    This podcast is powered by Pinecast.

    Toon meer Toon minder
    19 min.
  • 116 - DAYBROKEN - Clinical Success, Commercial Questions
    1 Oct 2026

    In this episode, I revisit Kodiak Sciences’ DAYBREAK readout for Zenkuda after getting the trade wrong. I break down what the 54% Q24 result really means, how the trial design and loading regimen may have shaped the durability headline, why payer step therapy could change the real-world patient population, and what I missed going into the catalyst. I also compare Zenkuda with Eylea HD and discuss what the data do—and don’t—tell us about the commercial opportunity for $KOD. #KodiakSciences #Biotech #BiotechStocks #WetAMD #Eylea #Regeneron #ClinicalTrials #Investing #BreakingBiotech

    Disclaimer: All opinions expressed by Matt (or his guests) in this podcast are solely his (their) opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt (nor his guests) cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt (nor his guests) is/are not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt (nor his guests) does/do not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech

    This podcast is powered by Pinecast.

    Toon meer Toon minder
    29 min.
  • 115 - Kodiak Sciences' Zenkuda takes on Eylea AGAIN in their DAYBREAK wet AMD P3 trial
    23 Sep 2026

    Kodiak Sciences ($KOD) is heading into a pivotal moment. The Phase 3 DAYBREAK readout in wet AMD could determine whether Zenkuda becomes a serious retinal franchise or whether Kodiak’s durability thesis breaks down again.

    In this episode, I break down the upcoming DAYBREAK Phase 3 trial in wet AMD, including what went wrong in the original DAZZLE study, why management believes the new trial design can rescue efficacy, and whether Zenkuda can still deliver enough durability to differentiate itself from Eylea HD and Vabysmo.

    The key question isn’t simply whether DAYBREAK succeeds. It’s whether Kodiak can fix DAZZLE’s efficacy problem without sacrificing the durability advantage that was supposed to make Zenkuda valuable in the first place.

    Disclaimer: All opinions expressed by Matt (or his guests) in this podcast are solely his (their) opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt (nor his guests) cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt (nor his guests) is/are not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt (nor his guests) does/do not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech

    This podcast is powered by Pinecast.

    Toon meer Toon minder
    38 min.